Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...
Ann Marie Rogers won a landmark victory to make the breast cancer drug Herceptin more widely available. Here, she explains what drove her. But others are asking if the treatment really lives up to ...
Cancer research saved my daughter’s life, and despite setbacks, we must support these efforts to ensure more lives are saved ...
Mr Kim said European payers have waited until both drugs are on the market before launching tenders, in order to drive a hard bargain on the price. Roche has had time to defend Herceptin against ...
and in the US manufacturers of branded drugs have become adept at constructing patent defences to prevent competition. The latest Herceptin biosimilar is branded as Kanjinti (trastuzumab-anns ...
HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung cancer (NSCLC), typically in female individuals, who are non-smokers, and have ...
Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...
AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...
An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback